Vita 34 AG
XETRA:V3V
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
DE |
Vita 34 AG
XETRA:V3V
|
74.4m EUR | -3.4 | ||
US |
Cigna Corp
NYSE:CI
|
99.2B USD | 13.1 | ||
US |
C
|
Cigna Group
XMUN:CGN
|
91.3B EUR | 12.9 | |
US |
CVS Health Corp
NYSE:CVS
|
69.1B USD | 8.6 | ||
DE |
F
|
Fresenius SE & Co KGaA
XETRA:FRE
|
15.9B EUR | 22.7 | |
US |
Laboratory Corporation of America Holdings
NYSE:LH
|
17.1B USD | 18 | ||
US |
Quest Diagnostics Inc
NYSE:DGX
|
15.2B USD | 14.6 | ||
DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.5B EUR | 16.2 | |
US |
DaVita Inc
NYSE:DVA
|
12.1B USD | 11.9 | ||
DE |
Fresenius Medical Care AG
XMUN:FME
|
11.3B EUR | 16.1 | ||
US |
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | -21.5 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.